See more : Jollibee Foods Corporation (JBFCF) Income Statement Analysis – Financial Results
Complete financial analysis of Mangoceuticals, Inc. (MGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mangoceuticals, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Ferrari N.V. (RACE.SW) Income Statement Analysis – Financial Results
- Millennium Online Solutions (India) Limited (MILLENNIUM.BO) Income Statement Analysis – Financial Results
- Plug Power Inc. (PLUG) Income Statement Analysis – Financial Results
- Clover Biopharmaceuticals, Ltd. (2197.HK) Income Statement Analysis – Financial Results
- B. Riley Principal 150 Merger Corp. (BRPM) Income Statement Analysis – Financial Results
Mangoceuticals, Inc. (MGRX)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.mangorx.com
About Mangoceuticals, Inc.
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 731.49K | 8.94K | 0.00 |
| Cost of Revenue | 299.99K | 4.09K | 0.00 |
| Gross Profit | 431.50K | 4.85K | 0.00 |
| Gross Profit Ratio | 58.99% | 54.26% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.45M | 2.00M | 70.08K |
| Selling & Marketing | 2.10M | 352.86K | -52.56K |
| SG&A | 8.55M | 2.00M | 17.52K |
| Other Expenses | 1.10M | 0.00 | 0.00 |
| Operating Expenses | 9.65M | 2.00M | 17.52K |
| Cost & Expenses | 9.95M | 2.00M | 17.52K |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.47K | 181.00 |
| Depreciation & Amortization | 24.89K | 3.86K | 70.08K |
| EBITDA | -9.19M | -1.99M | 52.56K |
| EBITDA Ratio | -1,256.00% | -22,236.48% | 0.00% |
| Operating Income | -9.22M | -1.99M | -17.52K |
| Operating Income Ratio | -1,260.28% | -22,279.70% | 0.00% |
| Total Other Income/Expenses | 6.47K | -6.47K | -53.28K |
| Income Before Tax | -9.21M | -2.00M | -17.70K |
| Income Before Tax Ratio | -1,259.40% | -22,352.11% | 0.00% |
| Income Tax Expense | 0.00 | -224.62K | -70.08K |
| Net Income | -9.21M | -2.00M | -17.70K |
| Net Income Ratio | -1,259.40% | -22,352.11% | 0.00% |
| EPS | -6.45 | -0.12 | 0.00 |
| EPS Diluted | -6.45 | -0.12 | 0.00 |
| Weighted Avg Shares Out | 1.43M | 17.32M | 17.32M |
| Weighted Avg Shares Out (Dil) | 1.43M | 17.32M | 17.32M |
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction...
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair...
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair...
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair...
MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair...
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair...
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction...
Why Is Mangoceuticals (MGRX) Stock Up 130% Today?
Mangoceuticals (NASDAQ: MGRX ) stock climbed up a staggering 130% at one point today after the company announced that its new oral formulations of its Semaglutide (“Slim”) and Tirzepatide (“Trim”) treatments have proven notably effective in clinical trials. What does...
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety...
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair...
Source: https://incomestatements.info
Category: Stock Reports